Study Overview: This study looks at a treatment plan for people with advanced pancreatic cancer. It combines a special type of radiation called stereotactic body radiotherapy (SBRT) with a mix of drugs: ipilimumab N01, sintilimab, nab-paclitaxel, and gemcitabine. The goal is to see if this treatment helps stop the cancer from growing and if it’s safe.
Key Points:
- Participants will get SBRT followed by drug treatments over several weeks, with regular check-ups.
- Eligible people must be 18-75 years old, have advanced pancreatic cancer without spread to other organs, and meet other health criteria.
- Regular monitoring will check if the cancer stops growing and assess any side effects.
Participants must be willing to follow all study guidelines and not be involved in other cancer trials. The main focus is on how long people live without their cancer getting worse (progression-free survival), alongside other health measures. Safety will be closely watched throughout.
How understandable was the trial content above?
Hard to understand
Easy to understand